AbbVie buys special review voucher for $350 mln
August 19, 2015 at 10:41 AM EDT
Aug 19 (Reuters) - AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs.
